Literature DB >> 17274665

Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.

Patricia L Mottram1, David Leong, Blessing Crimeen-Irwin, Simone Gloster, Sue D Xiang, Jayesh Meanger, Reena Ghildyal, Nicholas Vardaxis, Magdalena Plebanski.   

Abstract

Previous studies compared uptake by dendritic cells (DC) of 20, 40, 100, 200, 500, 1000, and 2000 nm beads in vivo. When beads were used as antigen carriers, bead size influenced antibody responses and induction of IFN-gamma-producing CD4 and CD8 T cells. Beads of 40-50 nm were taken up preferentially by DC and induced particularly strong immunity. Herein, we examine immunity induced by minute differences in nanobead size, specifically within a narrow viral-sized range (20, 40, 49, 67, 93, 101, and 123 nm), to see if bead carrier size influenced the induction of type 1 or type 2 cells as demonstrated by the production of IFN-gamma or IL-4. In vivo uptake by DC was assessed for selected sizes in this range. Responses to whole ovalbumin (OVA) or the OVA-derived CD8 T cell peptide epitope (SIINFEKL) were tested. After one immunization with beads-OVA, IFN-gamma responses to both OVA and SIINFEKL were significantly better with 40 and 49 nm beads than other sizes, while, in contrast, IL-4 responses to OVA were higher after immunization with OVA conjugated to larger beads (93, 101, and 123 nm). Thus IFN-gamma induction from CD8 T cells was limited to 40-49 nm beads, while CD4 T cell activation and IL-4 were induced by 93-123 nm beads-OVA. After two immunizations, there were comparable high levels of IFN-gamma produced with 40 and 49 beads and IL-4 reactivity was still higher for larger beads (93, 101, 123 nm). Production of IgG1 was seen across the full range of bead sizes, increasing after two immunizations. Since protection against respiratory syncytial virus (RSV) depends on strong IFN responses, while IL-4 responses are reported to cause asthma-like symptoms, immunization with RSV antigens on the 49 nm carrier beads could provide the basis for a suitable vaccine. When the 49 nm beads were conjugated to RSV proteins G88 (surface) or M2.1 (internal capsid), one immunization with G88 induced high levels of IFN-gamma and low levels of IL-4. IL-4 increased with two immunizations. Beads-M2.1 induced only moderate levels of IFN-gamma and low titer antibody after two immunizations. Mice vaccinated once with G88-conjugated 49 nm beads and challenged intranasally with RSV strain A2 subtype showed reduced viral titers and recovered from weight loss more rapidly than mice immunized with M2.1-conjugated 49 nm beads or naive control mice. These results show that precise selection of nanobead size for vaccination can influence the type 1/type 2 cytokine balance after one immunization, and this will be useful in the development of effective vaccines against common human pathogens such as RSV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17274665     DOI: 10.1021/mp060096p

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  80 in total

1.  The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen.

Authors:  Alexandra Mant; Fay Chinnery; Tim Elliott; Anthony P Williams
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

2.  Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design.

Authors:  Xinran Li; Brian R Sloat; Nijaporn Yanasarn; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2010-12-21       Impact factor: 5.571

Review 3.  Particle based vaccine formulations for transcutaneous immunization.

Authors:  Ankit Mittal; Anne S Raber; Claus-Michael Lehr; Steffi Hansen
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

4.  The type of adjuvant strongly influences the T-cell response during nanoparticle-based immunization.

Authors:  Torben Knuschke; Matthias Epple; Astrid M Westendorf
Journal:  Hum Vaccin Immunother       Date:  2013-08-27       Impact factor: 3.452

Review 5.  Nanoparticles and the immune system.

Authors:  Banu S Zolnik; Africa González-Fernández; Nakissa Sadrieh; Marina A Dobrovolskaia
Journal:  Endocrinology       Date:  2009-12-16       Impact factor: 4.736

6.  Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices.

Authors:  Santiswarup Singha; Kun Shao; Yang Yang; Xavier Clemente-Casares; Patricia Solé; Antonio Clemente; Jesús Blanco; Qin Dai; Fayi Song; Shang Wan Liu; Jun Yamanouchi; Channakeshava Sokke Umeshappa; Roopa Hebbandi Nanjundappa; Pascal Detampel; Matthias Amrein; César Fandos; Robert Tanguay; Susan Newbigging; Pau Serra; Anmar Khadra; Warren C W Chan; Pere Santamaria
Journal:  Nat Nanotechnol       Date:  2017-04-24       Impact factor: 39.213

Review 7.  Cytokines as biomarkers of nanoparticle immunotoxicity.

Authors:  Mahmoud Elsabahy; Karen L Wooley
Journal:  Chem Soc Rev       Date:  2013-06-21       Impact factor: 54.564

Review 8.  The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction.

Authors:  Nazanin Hoshyar; Samantha Gray; Hongbin Han; Gang Bao
Journal:  Nanomedicine (Lond)       Date:  2016-03-22       Impact factor: 5.307

9.  Bacterial polyester inclusions engineered to display vaccine candidate antigens for use as a novel class of safe and efficient vaccine delivery agents.

Authors:  Natalie A Parlane; D Neil Wedlock; Bryce M Buddle; Bernd H A Rehm
Journal:  Appl Environ Microbiol       Date:  2009-10-16       Impact factor: 4.792

10.  Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Authors:  Thomas J Powell; Jie Tang; Mary E Derome; Robert A Mitchell; Andrea Jacobs; Yanhong Deng; Naveen Palath; Edwin Cardenas; James G Boyd; Elizabeth Nardin
Journal:  Vaccine       Date:  2013-02-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.